Active Biotech AB

Equities

ACTI

SE0001137985

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:58 2024-05-03 am EDT			5-day change	1st Jan Change
0.54 ^SEK	-1.46%		-4.76%	+18.29%

Apr. 03	Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops	CI
Feb. 08	Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Active Biotech : Redeye initiates coverage of Active Biotech

December 14, 2020 at 02:15 am EST

Redeye initiates coverage of Active Biotech with a cautiously optimistic view on the new strategic direction. Increased clinical activity sets the shares up for several catalysts during the next year. The Company is currently raising SEK 76m in a Rights Issue. If the capital raise is fully subscribed, we calculate a base case of SEK 3 per share.

Read more and download the Research Report

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Latest news about Active Biotech AB

Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops	Apr. 03	CI
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 08	CI
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
Active Biotech AB Provides Update on the Scheduled Clinical Program for 2024	Dec. 22	CI
Active Biotech Raises SEK44 Million via Rights Offering	Dec. 06	MT
Active Biotech Teams Up with US Research Group on Clinical Study of Laquinimod Eye Drops	Dec. 06	MT
Active Biotech AB Appoints Mats Arnhög and Petter Wingstrand to Nomination Committee	Dec. 01	CI
Active Biotech Plans SEK51 Million Rights Issue; Shares Sink	Nov. 09	MT
Active Biotech AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Active Biotech AB Announces Two Abstracts with Preclinical Data for Tasquinimod in Myelofibrosis and Myelodysplastic Syndrome Have Been Accepted for Presentation At Ash 2023	Nov. 02	CI
Active Biotech AB Announces Successful Completion of Dose Escalation of Tasquinimod	23-09-11	CI
Active Biotech AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Active Biotech Signs Collaboration Deal For Blood Cancer Drug Clinical Trial	23-07-31	MT
Active Biotech AB Enters into Clinical Trial Collaboration Agreement for a Clinical Study with Tasquinimod in Myelofibrosis	23-07-31	CI
Active Biotech Announces Positive Interim Data from an Ongoing Study with Tasquinimod in Relapsed and Refractory Multiple Myeloma	23-05-26	CI
Active Biotech AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Active Biotech AB Auditor Raises 'Going Concern' Doubt	23-04-25	CI
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-09	CI
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-09	CI
Active Biotech AB Confirms Positive Clinical Safety Profile of Laquinimod Eye Drops	23-01-30	CI
Active Biotech's Announces Nomination Committee	22-12-05	CI
Active Biotech AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Active Biotech AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04	CI
Active Biotech AB Announces Successful Completion of the First Stage of the Phase Iia Clinical Trial of Naptumomab in Combination with Docetaxel and the Study Is Now Enrolling into the Second Stage	22-06-01	CI
Active Biotech AB announces that Food and Drug Administration has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis	22-05-18	CI

Chart Active Biotech AB

Duration

Period

More charts

Company Profile

Active Biotech AB (publ) is a Sweden-based Company, which develops pharmaceutical products within medical areas where the immune defense is important, including cancer and inflammatory diseases. The project portfolio comprises both small, orally active immunomodulatory molecules and antibody-based immunotherapy.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ACTIVE BIOTECH AB	+18.29%	18.08M
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B

Bio Therapeutic Drugs